Chemical compounds

G1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer

Retrieved on: 
Monday, July 19, 2021
Organic compounds, Chemical compounds, G1 Therapeutics, Chemistry, Breakthrough therapy, Trilaciclib, G1

Fast Track designation underscores the urgent need for innovative drugs that can significantly improve TNBC patient outcomes, said Raj Malik, M.D., Chief Medical Officer at G1 Therapeutics.

Key Points: 
  • Fast Track designation underscores the urgent need for innovative drugs that can significantly improve TNBC patient outcomes, said Raj Malik, M.D., Chief Medical Officer at G1 Therapeutics.
  • It provides an important pathway to help expedite the development and regulatory review of COSELA in this indication.
  • G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics .
  • G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.

Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021

Retrieved on: 
Monday, July 19, 2021
Professional services, Medical devices, Health, Finance, Pharmaceutical, Optical, Health, Food and Drug Administration, Chemical compounds, Muscarinic antagonists, Phenols, Pyridines, Tropicamide, Phenylephrine, Mydriasis, Prescription Drug User Fee Act, PDUFA date, Myopia, Eyecelerator, ASCRS, EYECELERATOR, ASCRS

A replay of the Ladenburg Thalmann presentation, which took place on July 14, can be found here .

Key Points: 
  • A replay of the Ladenburg Thalmann presentation, which took place on July 14, can be found here .
  • Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics.
  • Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis.
  • The companys lead product candidate, Mydcombi (tropicamide/phenylephrine fixed combination) for use in diagnostic eye exams, has an FDA PDUFA date of October 28, 2021.

Xenikos Announces T-Guard® Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives

Retrieved on: 
Monday, July 19, 2021
Chemical compounds, Medical specialties, Clinical medicine, Cyclopentanes, Nitriles, Pyrazoles, Ruxolitinib, Hematopoietic stem cell transplantation

Xenikos expects to commence this Phase 3 study in the second half of 2021.

Key Points: 
  • Xenikos expects to commence this Phase 3 study in the second half of 2021.
  • Initiate new Phase 3 study evaluating T-Guard versus ruxolitinib in patients with SR-aGVHD following allo-HSCT in the second half of 2021.
  • Complete safety run-in phase of Phase 3 study mid 2022.
  • Mehdi Hamadani, Protocol Officer, Scientific Director of CIBMTR, Medical College of Wisconsin; John Levine, Protocol Co-chair, Director of BMT Clinical Research, Mt.

Bereaved Parents Create Non-Profit to Combat Fentanyl Epidemic

Retrieved on: 
Sunday, July 18, 2021
Psychoactive drugs, Anilides, Piperidines, Synthetic opioids, Drugs, Chemical compounds, Designer drugs, Janssen Pharmaceutica, Fentanyl

Fentanyl, a cheap and powerful opioid, is the primary driver of the dramatic increase in drug deaths over the past year, according to the CDC .

Key Points: 
  • Fentanyl, a cheap and powerful opioid, is the primary driver of the dramatic increase in drug deaths over the past year, according to the CDC .
  • "Educating kids and families about the real dangers of fentanyl is just as important as monitoring platforms for drug activity.
  • In addition, Snap will also run a special episode of its award-winning news show, Good Luck America (GLA), devoted to the fentanyl epidemic and featuring an interview with Ed Ternan.
  • "We are honored to partner with Song for Charlie to educate young people on the dangers of counterfeit drugs and fentanyl poisoning.

Neutrogena Beach Defense and Ultra Sheer aerosol spray sunscreens recalled due to elevated benzene levels

Retrieved on: 
Saturday, July 17, 2021
Chemical compounds, Chemical substances, Chemistry, Benzene, Mutagens, Soil contamination, Teratogens, Sunscreen, Johnson & Johnson

Product: Neutrogena Beach Defense and Ultra Sheer sunscreens, for adults and children, in aerosol spray format.

Key Points: 
  • Product: Neutrogena Beach Defense and Ultra Sheer sunscreens, for adults and children, in aerosol spray format.
  • Issue: Johnson & Johnson Inc. is recalling all lots of Beach Defense and Ultra Sheer aerosol spray sunscreens due to elevated levels of benzene, which may pose serious health risks after long-term, repeated use.
  • Johnson & Johnson Inc. is recalling all lots of Neutrogena Beach Defense and Ultra Sheer children and adult sunscreens, in aerosol spray format, after testing conducted by the company detected elevated levels of benzene.
  • Frequent and long-term exposure (e.g., through the skin and by inhalation) to elevated levels of benzene may pose serious health risks.

ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19

Retrieved on: 
Saturday, July 17, 2021
AIDS, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Integrase inhibitors, Non-nucleoside reverse transcriptase inhibitors, Organic compounds, Nitriles, Pyrimidines, Rilpivirine, Cabotegravir, Prevention of HIV/AIDS, HIV Prevention Trials Network, Cabenuva (cabotegravir and rilpivirine)8, ViiV Healthcare, GSK, CABENUVA (CABOTEGRAVIR AND RILPIVIRINE)8, VIIV HEALTHCARE, GSK

Additionally, this regimen remained highly acceptable both to healthcare providers and people living with HIV and was strongly preferred by study participants to daily oral therapy.

Key Points: 
  • Additionally, this regimen remained highly acceptable both to healthcare providers and people living with HIV and was strongly preferred by study participants to daily oral therapy.
  • A corresponding trial in Europe, CARISEL, is examining the implementation of long-acting cabotegravir and rilpivirine, dosed every 2-months in certain European healthcare settings.
  • Marketing Authorisations for the long-acting regimen of cabotegravir and rilpivirine were granted by the European Medicines Agency in December 2020.
  • Sustainment of implementation strategies was assessed via surveys and semi-structured interviews of staff study participants as well as patient study participants.

New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor

Retrieved on: 
Saturday, July 17, 2021
AIDS, Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Medical specialties, Hepatotoxins, Prevention of HIV/AIDS, HIV/AIDS, Management of HIV/AIDS, Zidovudine, HIV, Lenacapavir, Discovery and development of HIV-protease inhibitors, HIV vaccine development

If approved, lenacapavir would be the first capsid inhibitor and the only HIV-1 treatment option administered every six months.

Key Points: 
  • If approved, lenacapavir would be the first capsid inhibitor and the only HIV-1 treatment option administered every six months.
  • Lenacapavir is a potentially first-in-class capsid inhibitor without overlapping resistance with any currently approved antiretroviral therapy (ART).
  • Lenacapavir is a potential first-in-class, long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV-1 infection.
  • Data presented at AIDS 2020 from a Phase 1 study support further evaluation of lenacapavir administered subcutaneously every six months for both HIV-1 treatment and prevention.

Pressure BioSciences, Inc. Discusses Historic CBD Nanoemulsion Stability Achievement and Astaxanthin Nanoemulsions with The Stock Day Podcast

Retrieved on: 
Friday, July 16, 2021
Chemical compounds, Astaxanthin, Carotenoids

President and CEO of the Company, Mr. Richard Schumacher, joined Stock Day host Everett Jolly.

Key Points: 
  • President and CEO of the Company, Mr. Richard Schumacher, joined Stock Day host Everett Jolly.
  • Mr. Schumacher continued: "Astaxanthin is in short supply and is not easy to obtain.
  • Mr. Jolly then asked about the Company's CBD stability achievement news: "Please explain the significance of this, and where you are in that process."
  • Experience has shown in CBD's case that it is even more difficult to effectively extract and absorb CBD in our bodies than for Astaxanthin.

Right on Brands Develops New THCV Vape and Tincture

Retrieved on: 
Friday, July 16, 2021
Cannabinoids, Tobacco, Psychoactive drugs, Chemical compounds, Electronic cigarettes, Tetrahydrocannabivarin, Natural phenols, Resorcinols, Electronic cigarette, Cannabidivarin, Onon, Suppression

Right on Brands is excited to offer to the public its latest new product which is now available in limited quantity on our website.

Key Points: 
  • Right on Brands is excited to offer to the public its latest new product which is now available in limited quantity on our website.
  • Go to www.thcvnano.com to learn the benefits of using THCV/CBDV/CBD/DELTA 8 combined in a vape or water-soluble tincture.
  • Some preliminary studies have shown that THCV may aid appetite suppression, regulation of blood sugar, reduce inflammation and aid motor control.
  • "Right On Brands in the last several weeks has been overwhelmed by early sales traffic at our corporate location fueling new interest in License ownership" says Jerry Grisaffi, CEO of Right Onon Brands.

Navitas and Xiaomi team up for the third time with world-class small size and featherweight mobile fast charging

Retrieved on: 
Friday, July 16, 2021
Chemistry, Chemical compounds, Gallium nitride, Nitrides, Xiaomi, Navitas, Telecommunications, Smartphones

Navitas' proprietary GaN power ICs integrate GaN power (FET) and GaN drive plus control and protection in a single SMT package.

Key Points: 
  • Navitas' proprietary GaN power ICs integrate GaN power (FET) and GaN drive plus control and protection in a single SMT package.
  • An estimated $13.1B electrification opportunity includes mobile fast chargers and adapters, data centers, solar energy, and EV.
  • Xiaomi attaches importance to both innovation and product quality, constantly pursuing a higher user-experience as well as better operational efficiency.
  • In power electronics, Navitas shares this same philosophy, meaning the Xiaomi 65W 1A1C GaN charger has impressed and won the hearts of consumers with excellent charging experience.